Accendra Health, Inc.

NYSE:ACH

Medical - Distribution

Healthcare
$0.71 +3.64%

+$0.12 today

Market cap
$54.22M
Beta
1.63
P/E (TTM)
-0.2
EPS (TTM)
-$14.11
52W Low $1.84High $9.55

Volume 1.41M

Average 0.83M

ACH Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Accendra Health, Inc.NYSE: ACH

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $3.09M fell 55.4% year over year, ahead of the -78.3% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at -15.0% a year.

Context

  • Stock-based compensation amounted to 0.5% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -55.4% holds above the trailing-twelve-month pace of -78.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.09M+169.3% QoQ
Last fiscal yearDec 2025
$12.87M-52.0% YoY
LTMMar 2026
$5.84M-78.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-55.4%——
1 year-52.0%——
3-year CAGR-15.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
12.87M USD
Year-over-year change
-52.0%
4-year CAGR
-15.3%

Stock-Based Compensation vs competitors

How ACH compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -78.3% is the lowest of 11, against a peer median of -16.3%.
  • Stock-based compensation amounts to 0.2% of revenue for ACH, versus a peer median of 17.1%.
ACH Competitors
Stock-Based Compensation for ACH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$33.74M USD-35.1%-23.4%—
CABACabaletta Bio, Inc.LTM Mar 2026$21.03M USD+1.0%+44.8%—
OMOutset Medical, Inc.LTM Mar 2026$16.09M USD-33.3%-16.9%13.7%
BIOABioAge Labs, Inc.LTM Mar 2026$13M USD+43.2%+66.3%126.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$12.05M USD-2.1%-6.3%144.0%
SGHTSight Sciences, Inc.LTM Mar 2026$11.67M USD-30.6%+0.2%14.7%
CVRXCVRx, Inc.LTM Mar 2026$11.51M USD+11.1%+41.7%19.5%
EDITEditas Medicine, Inc.LTM Mar 2026$9.12M USD-45.7%-30.1%23.6%
ACHAccendra Health, Inc.LTM Mar 2026$5.84M USD-78.3%-15.0%0.2%
CGCCanopy Growth CorporationLTM Mar 2026CA$4.6M CAD+209.3%-38.3%1.5%
HITIHigh Tide Inc.LTM Apr 2026CA$1.86M CAD-54.1%-21.4%0.3%
Peer median (excluding ACH) —-16.3%-11.6%17.1%

Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income221.59M22.39M(41.3M)(362.69M)(102.68M)
Depreciation & Amortization90.62M228.67M287.38M264.78M214.52M
Deferred Income Tax(29.74M)(26.36M)(23.65M)(26.12M)(17.89M)
Stock-Based Compensation25.02M20.99M23.22M26.84M12.87M
Change in Working Capital(261.4M)89.77M522.29M(25.44M)65.21M
Accounts Receivables(2.2M)1.1M166.58M(94.55M)122.36M
Inventory(263.44M)166.56M224.34M(26.23M)(6.85M)
Accounts Payables3.55M13.65M31M65.19M6.48M
Other Working Capital692K(91.54M)100.37M30.15M(56.78M)
Other Non-Cash Items78.09M(10.45M)(27.22M)284.12M(273.83M)
Operating Cash Flow124.18M325.01M740.71M161.5M(101.79M)
Capital Expenditures(49.69M)(166.58M)(207.89M)(228.16M)(201.33M)
Acquisitions (Net)(43.37M)(1.68B)00324.26M
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities39.43M46.71M53.62M94.33M11.12M
Investing Cash Flow(53.63M)(1.8B)(137.25M)(116.53M)144.42M
Debt Repayment(95.35M)1.58B(416.69M)(244.2M)203.5M
Common Stock Issued00000
Common Stock Repurchased0000(10.18M)
Dividends Paid(731K)0000
Other Financing Activities(33.4M)(85.4M)(637K)(23.41M)(5.24M)
Financing Cash Flow(129.48M)1.5B(417.33M)(267.6M)188.08M
Effect of Forex Changes(3.54M)(3.49M)613K(901K)1.9M
Net Change in Cash(62.47M)14.15M186.74M(223.54M)232.61M
Free Cash Flow74.49M158.42M532.82M(66.67M)(303.12M)

Accendra Health, Inc.

NYSE:ACH

Intrinsic Alpha fair value

Locked

Current Price

$0.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.